학술논문
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL
Document Type
Article
Author
Source
In: RMD Open . (RMD Open, 22 February 2024, 10(1))
Subject
Language
English
ISSN
20565933